Relugolix, Estradiol, and Norethindrone Acetate (Myfembree)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses relugolix-estradiol–norethindrone acetate (Myfembree) 40 mg/1 mg/0.5 mg, oral tablet. Indication: In premenopausal women for the management of heavy menstrual bleeding associated with uterine fibroids and for the management of moderate to severe pain associated with endometriosis.